Glucotrack, Inc.
For the period ended Jun 30, 2026. Filed Aug 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 14, 2026
GCTK$1.39-32.2%Stored close · as of Oct 29, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
(in thousands of US dollars except share data) (unaudited)
| Six-month period ended June 30, | Three-month period ended June 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Operating expenses | ||||
| Research and development expenses | $4,148 | $5,021 | $2,016 | $3,150 |
| General and administrative expenses | 3,455 | 3,273 | 1,384 | 1,646 |
| Total operating expenses | 7,603 | 8,294 | 3,400 | 4,796 |
| Operating loss | 7,603 | 8,294 | 3,400 | 4,796 |
| Other (income) expense | ||||
| Change in fair value of derivative Liabilities | (1) | 3,269 | - | (107) |
| Other (income) expense, net | 546 | 92 | 414 | 96 |
| Finance income, net | - | (66) | - | (29) |
| Net Loss | 8,148 | 11,589 | 3,814 | 4,756 |
| Other comprehensive income: | ||||
| Foreign currency translation adjustment | (11) | (65) | (8) | (29 |
| Comprehensive loss for the period | $8,137 | $11,524 | $3,806 | $4,727 |
| Basic and diluted net loss per common stock | $2.44 | $34.81 | $0.76 | $9.62 |
| Weighted average number of common stock used in computing basic and diluted loss per common stock | 3,332,919 | 332,931 | 5,009,085 | 494,504 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.